Introduction
Glutaredoxins (Glrxs) belong to the members of the thioredoxin (Trx) superfamily of thiol/disulfide exchange catalysts, and hence known as thioltransferase, which serves as reductants of protein-SG-mixed disulfides that provide reducing equivalents to ribonucleotide reductase. 1 In mammalian system, Glrx exist in two major forms-Glrx-1 localizes in the cytosol and Glrx-2 localizes primarily in the mitochondria, but can also localize in the nucleus. 2 Both Glrx-1 and Glrx-2 have a crucial function in redox regulation and protect cells against apoptosis. 2 A recent study showed that overexpression of Glrx-1 by ischemic preconditioning and transgenic mice overexpressing Glrx-1 were resistant to myocardial ischemic-reperfusion injury. 3 Glutathione together with glutathione enzyme system and thioltransferase have a crucial function in defense against reactive oxygen species (ROS) that are potential hazards against a variety of degenerative diseases including ischemic heart disease, cardiomyopathy, hypertension, atherosclerosis, diabetes, and heart failure. 4 Reduced levels of glutathione, glutathione utilizing enzymes, and thioltransferase were found in the platelets of diabetic patients. 5 Glrx-1 level was reported to be reduced after brain ischemia. 6 Glrx and Trx were found to be enhanced in human coronary arteries, where they were suggested to protect vascular cells in normal conditions as well as against elevated oxidative stress in atherosclerotic lesions. 7 An increased level of Glrx-1 was seen in the hearts of diabetic rats, 8 where it was shown that K + channels underlying Ito are regulated in a redox sensitive manner via the Trx system. In addition to that, an upregulation of Glrx-1 was seen in the eye of diabetic rats. 9 High amount of Glrx mRNA and protein was found in pancreatic b-cells, where NADPH/Glrx/ Trx redox regulation was shown to mediate nutrientinduced insulin secretion. 10 Upregulation of Glrx-1 in the diabetic animals denotes an adaptive response to mitigate the challenge of redox unbalance during the initial phase of diabetes. During the advanced phase, however, the antioxidants including Glrx-1 fall indicating a failed adaptive response.
The above reasons indicate that Trx/Glrx system not only has a crucial function in the redox regulation in the ischemic heart, but also helps maintaining the redox homeostasis in diabetic hearts. This study was designed to examine the effects of Glrx-1 gene therapy in the diabetic myocardium whether it could ameliorate the cardiovascular risks associated with diabetes and ischemia-reperfusion. The results of this study documented that upregulation of Glrx-1 through Glrx-1 gene therapy could reduce cardiac complications in diabetic heart associated with ischemia-reperfusion.
Results
Glrx-1 gene therapy enhanced the expression of Glrx-1 protein First, we evaluated whether our gene therapy was successful by examining the expression of Glrx-1 in the heart by immunohistochemistry. As shown in Figure 1a , Glrx-1 was highly expressed in the heart after the Ad-Glrx-1 gene therapy, whereas only a low level of Glrx-1 was detected in the Ad-Ev and Ad-LacZ groups indicating the success of gene delivery. To further confirm the success of the gene delivery, western blot analysis was performed as shown in Figure 1b . Thus, the expression was higher in Ad-Glrx-1 injected group, and it remains higher also after ischemia-reperfusion compared with the Ad-Ev or Ad-LacZ group.
Effect of Glrx-1 gene therapy on diabetic mouse heart function determined by M-mode echocardiography M-mode echocardiography was performed both before and after gene delivery in randomly assigned groups. Animals from each group underwent successive echocardiography after proper induction of anesthesia before surgery and after 4 days of delivering Ad-EV, Ad-LacZ, or Ad-Glrx-1. No significant difference was found between pre-and post-surgery groups with any of the vectors (Figure 2 ).
Glrx-1 gene therapy improved ventricular recovery in isolated diabetic mouse hearts
To assess whether Glrx-1 gene therapy helps the diabetic hearts against ischemia-reperfusion injury, the isolated hearts obtained from the diabetic animals injected with Ad-Ev, Ad-LacZ, or Ad-Glrx-1 were subjected to 30 min of global ischemia followed by 120 min of reperfusion. Glrx-1 gene therapy in diabetic heart I Lekli et al At baseline, there were no significant differences in left ventricular (LV) functional parameters between groups ( Figure 3 ). After ischemia/reperfusion (I/R), the Glrx-1 hearts showed improved LV function, including improved aortic flow, LVDP, and LVdp/dt compared with the Ad-Ev and Ad-LacZ groups. Coronary flow did not show any significant differences.
Glrx-1 gene therapy reduced the I/R-mediated myocardial infarct size and cardiomyocyte apoptosis in diabetic heart
As shown in Figure 4a , after 30 min of global ischemia and 120 of reperfusion, there were no significant differences in infarct size measured by triphenyl tetrazolium chloride (TTC) method between Ad-EV and Ad-LacZ group, but Ad-Glrx-1-treated group exhibited significantly less infarct. Figure 4b shows the cardiomyocyte apoptosis assessed by TUNEL staining. At baseline, there were no significant differences between the groups; however, after I/R in Ad-Glrx-1 group, the numbers of the apoptotic cells were significantly lower in comparison with Ad-EV and Ad-LacZ groups.
As shown in Figure 4c , procaspase-3 level was similar among the groups in baseline condition. After I/R, procaspase-3 level was significantly reduced in case of empty vector or LacZ-treated diabetic hearts, whereas in Glrx-1-treated group, the procaspase-3 level remained higher.
Glrx-1 gene therapy inhibited I/R-mediated apoptotic signaling in diabetic myocardium
To determine the mechanisms by which Glrx-1 gene could inhibit the death signal generated in the diabetic heart after I/R, we monitored apoptotic signaling proteins such as Ask-1, Jnk, c-Src, and p38 mitogenactivated protein kinase (MAPK). Figure 5 shows that Ask-1, p38 MAPK, Jnk, and c-Src were phosphorylated even at the baseline level. Among the groups, the level of the p-Ask in the Ad-Glrx-1 group was the highest at the baseline level, which remained at the same level even after ischemia, indicating the inhibition of the Ask. The level of p-Jnk before and after ischemia was decreased in Glrx-1 group compared with the other two groups. Similar to p-Jnk, the p-p38 MAPK was also lower in the Ad-Glrx-1 group at baseline and after I/R in comparison with both Ad-Ev and Ad-LacZ groups. The level of p-c-Src also showed the same pattern as was observed in case of p-Jnk.
Glrx-1 gene therapy induced the activation of survival proteins in diabetic myocardium
As a measure of Glrx-1-induced survival proteins, we monitored the activation of Akt and FoxO-1 as well as Glrx-1 gene therapy in diabetic heart I Lekli et al endothelial nitric oxide synthase (e-NOS) and HO-1. As depicted in Figure 6 , the level of p-Akt was higher in Ad-Glrx-1 group both at baseline and after ischemiareperfusion compared with the other two groups. Extensive phosphorylation of FoxO-1 occurred after Glrx-1 gene therapy as compared with Ad-Ev and Ad-LacZ groups both at baseline and after I/R (Figure 6a ). The activation of e-NOS and HO-1 is shown at the bottom of Figure 6 . Ad-Glrx-1 treatment enhanced the level of e-NOS and HO-1 both at baseline and after ischemia-reperfusion compared with Ad-Ev or Ad-LacZ groups.
Discussion
The salient features of this study include that Glrx-1 gene therapy in diabetic hearts (1) improved ventricular recovery, and reduced myocardial infarct size and cardiomyocyte apoptosis, indicating that Glrx-1 treatment reduces the ischemia-reperfusion-induced injury in diabetic heart; (2) attenuated death signaling molecules, including c-Src, p38 MAPK, Jnk; and (3) enhanced survival signaling molecules, including activation of Akt, FoxO-1, HO-1 a cardioprotective phase II enzyme, and e-NOS. Glrxs belong to the Trx superfamily of thiol/disulfide exchange catalysist, and therefore known as thioltransferases. Four different Glrxs have been identified in the mammalian cells, including Glrx-1, Glrx-2, monothiol Glrx-3 (PICOT), and Glrx-5. 2, 11, 12 Glrx1 is the most well-characterized gene of the Glrx family proteins. It is a 12-kDa protein that mainly resides in cytosol, but can be translocated to the nucleus after certain stimuli. Glrx-1 is ubiquitously present in the mammalian tissues including heart. A recent study also showed the existence of Glrx-1 in mitochondrial intermembrane space. 13 Glrx-1 seems to have a function in cardioprotection primarily functioning as an antioxidant. A recent study showed that the level of myocardial Glrx-1 was not affected by I/R, but it was significantly increased by preconditioning of the heart to ischemic stress. 3 Moreover, the hearts of the Glrx-1 Tg/+ transgenic animals exhibited more resistance against I/R injury. Blocking the effects of Glrx-1 with cadmium made the preconditioned hearts more susceptible to I/R injury, suggesting that the overexpression of Glrx-1 could reduce the ischemic injury. 3 The involvement of ROS in concert with the deficit of antioxidant reserve 14 is a well-known etiology for the deterioration of the diabetic myocardium. One of the consequences of the ROS is oxidative modification of proteins that involve the reactivity of the free SH group of the cysteine residues. 15 The active site of Glrx-1 has a Cys-Pro-Tyr-Cys-motif, and it can catalyze the reduction of protein-mixed disulfides and can regulate the SH repair mechanisms thereby controlling the function of the proteins susceptible for oxidation. 2 Thus, it is not surprising that Glrx-1 can protect the heart presumably by protecting the SH group preserving cysteine residues.
Glrx-1 inhibits apoptosis by functioning as a negative regulator of Ask-1 through its ability to inhibit Ask-1 Glrx-1 gene therapy in diabetic heart I Lekli et al and its subsequent signal transduction pathway 16, 17 involving Jnk, and p38 MAPK, leading to apoptosis. Moreover, the phosphorylation of Ask-1 at Ser 83 by Akt suppress Ask-1 activity and Ask-1-mediated apoptosis. 18, 19 Consistent with the earlier reports, our results show that Glrx-1 therapy could also inhibit the Ask activation as well as the activation of Jnk and p38 MAPK and suppressed the apoptosis.
Glrx-1 protects the cells against apoptosis through the regulation of Akt redox status. 20 The activated Akt on one hand phosphorylates Ask-1 at the Ser 83 site to inhibit its activation, and on the other hand it phosphorylates FoxO. Phosphorylation of FoxO by Akt decreases its DNA-binding capacity and translocates it from the nucleus to the cytosol, 21 where it gets degraded after ubiquitinylation, leading to cell survival. Our results indicate that Glrx-1 gene therapy activates the Akt-FoxO1 pathway simultaneously suppressing the Ask-Jnk-p38 pathway.
In summary, adenovirus-mediated Glrx-1 gene therapy in diabetic hearts enhanced the amount of Glrx-1. In concert, these hearts restored the reduced LV function associated with diabetes and I/R. Glrx-1 gene therapy attenuated myocardial infarction, apoptosis, and death signals mediated through Ask-1/Jnk/p38 MAPK pathway associated with diabetes and I/R, and enhanced the survival signals including the phosphorylation of Akt, FoxO-1 and induced e-NOS, and cardioprotective phase II enzyme HO-1. Our results suggest that Glrx-1 gene therapy protects the heart via redox regulation of Akt and seems to form a signaling network involving Ask-1/ Jnk/p38 MAPK and Akt-FoxO-1, which switch diabetes and/or ischemia-reperfusion-induced death signal into a survival signal. The extrapolation of our findings Male C57B6J mice (The Jackson Laboratory, Bar Harbor, ME, USA) between 23-28 g were fed ad libitum regular mice chow with free access to water until the start of the experiment.
Materials and methods

Generation of recombinant adenoviruses carrying an myc-tagged human Glrx-1 cDNA
The entire cDNA fragment coding for the human Glrx-1 (IMAGE clone 346606, NCBI accession W79548) was initially released from the plasmid vector pT7T3 by digestion with enzymes EcoRI and NotI and then ligated into the corresponding restriction sites in vector pcDNA3.1(+) (Invitrogen, Carlsbad, CA, USA). The resultant plasmid was used as a template for polymerase chain reaction using forward primer 5 0 -GTTTAAACTT AAGCTTGGTACCGAGCTCGG-3 0 [corresponding to the multiple cloning site of pcDNA3.1(+)] and reverse primer 5 0 -CTAGTCGACCTGCAGAGCTCCAATCTGCT TTAGC-3 0 (for insertion of an SalI restriction site after the last amino acid of the human Glrx-1 protein). The polymerase chain reaction-amplified DNA fragment was digested with enzymes BamHI and SalI, followed by cloning into the corresponding restriction sites in vector pCMV-Tag 1 (Stratagene, La Jolla, CA, USA). This allows fusion of an myc peptide to the C-terminus of the human Glrx-1 protein. The entire cDNA fragment encoding the myc-tagged human Glrx-1 was subsequently isolated from the vector by digestion with enzymes BamHI and KpnI, and then cloned into the corresponding sites in vector pUC19. The cDNA fragment in the pUC19 vector, which is flanked by two EcoRI restriction sites, was finally inserted into the EcoRI site in vector pENTR2B (Invitrogen), resulting in a plasmid named pENTR-TGlrx-1. An adenoviral vector with Ad5 backbone, in which the myc-tagged human Glrx-1 cDNA is driven by the human cytomegalovirus (CMV) immediate-early promoter, was then generated by the LR Clonase-catalyzed site-specific recombination reaction between plasmids pENTR-TGlrx-1 and pAD/CMV/ V5-DEST following the protocol recommended by the manufacturer (Invitrogen). The entire recombinant adenoviral sequence was finally released from the plasmid by digestion with enzyme PacI and then transfected into 293A cells for production of recombinant viruses. Recombinant adenoviruses were also generated from the same adenoviral vector without the inserted myc-tagged human Glrx-1 cDNA (pAd/CMV/V5-DEST) and with the insertion of the Escherichia coli bgalactosidase gene (pAd/CMV/V5-GW/LacZ) for the use as controls.
Induction of diabetes
After 4 h of fasting period, streptozotocin dissolved in citrate buffer (pH 4.5), was injected intraperitoneally with a dose of 150 mg kg À1 bodyweight. After 8 days, the diabetes was verified by markedly increased blood sugar level 4400 mg per 100 ml (457±15 in Ad-Ev, 468±19 in Ad-LacZ, and 449 ± 17 in Ad-Glrx-1).
Surgical procedure
Survival surgery in mice was performed as mentioned in our earlier study. 22 To induce anesthesia, ketamine (100 mg kg À1 ) and xylazine (2 mg kg À1 ) were injected intraperitoneally. Bupernorphine hydrochloride (0.1 mg kg À1 ) was used as analgesic agent and gentamycin (1 mg kg À1 ) were used as antibiotic to prevent infections. After intubation, mice were artificially ventilated using a small animal ventilator (MINIVENT mouse ventilator model 845, Harvard Apparatus). Small thorachotomy were performed lateral to the midsternal line in the fourth intercostal place, and vectors either empty or LacZ or Glrx-1 encoded, were injected into three different places into the anterior wall of the left ventricle between the left anterior descending artery and the left arterial branch, using a 30-gauge needle (2 Â 10 10 -PFU ml À1 , final volume was 10 ml). After the delivery of the vector, the chest was closed with 6-0 suture layer by layer, and mice were allowed to recover.
M-mode echocardiography
After confirming diabetes, the mice were anesthetized with isoflurene, shaved, and placed on a heated pad. Transthoracic two-dimensionally guided M-mode echocardiography was performed using a Vevo 770 (Visual-Sonics Inc., Toronto, ON, Canada) ultrasound system equipped with a 25-MHz transducer (Vevo 770) to visualize the left ventricle. The functional parameters measured were as follows: percentage of LV, fractional shortening, LV ejection fraction, and heart rate. The process was performed 4 days after gene delivery. 23 
Isolated heart preparation and cardiac function assessment
After 4 days of gene delivery, the mice were anesthetized with pentobarbital (80 mg kg À1 b/w i.p. injection) (Abbott Laboratories, North Chicago, IL, USA), and heparin sodium (500 IU kg À1 b/w i.p. injection) (Elkin-Sinn Inc., Cherry Hill, NJ, USA) was given as anticoagulant. After sufficient deep anesthesia, thorachotomy was performed; hearts were excised, and perfused with modified Krebs-Henseleit bicarbonate buffer (millimolar concentration: sodium chloride 118, potassium chloride 4.7, calcium chloride 1.7, sodium bicarbonate 25, potassium biphosphate 0.36, magnesium sulfate 1.2 and glucose 10, and after its oxygenization pH was 7.4 at 37 1C) according to Langendorff method without pacing. After 10 min of wash out period, the preparation was switched to the working mode for 10 min. At the end of the 10 min in working mode, baseline cardiac parameters (aortic flow, coronary flow, left ventricle develop pressure (LVDP) and
Glrx-1 gene therapy in diabetic heart I Lekli et al first derivative of developed pressure LVdp/dt)) were recorded, and ischemia was initiated. After 30 min of global ischemia, the hearts were reperfused with KHB buffer for 120 min, and cardiac functions were recorded after 30-, 60-, and 120 min of reperfusion. Aortic and coronary flows were measured by time collecting effluents dripping from the heart. Other parameters including LVDP and LVdp/dt were assessed from the continuously obtained pressure signal using a Gould 6600 series signal conditioner (Gould Instrument Systems Inc, Valley View, OH, USA) and monitored on a CORDAT II real-time data acquisition and analysis system (Triton Technologies, San Diego, CA, USA). 24 
Infarct size estimation
At the end of the experiments, 1% (w/v) solution of TTC in phosphate buffer was infused through the aortic cannula at 37 1C, after the hearts were stored at À70 1C for subsequent analysis. The hearts were sliced into 1.2 mm thickness of cross-sectional pieces, and were fixed in 2% paraformaldehyde, placed between two cover slips and digitally imaged using a Microtek ScanMaker 600z. To quantitate the areas of infarct in pixels, a NIH image 5.1 (a public-domain software package) were used. The infarct size was quantified and expressed in pixels. 22 
Immunofluorescence analysis
Deparaffinized heart tissue sections were incubated with Glrx-1 antibody (1:25 dilution) for 2 h at room temperature. Alexa Fluor 594 (2 mg ml À1 ) was used as secondary antibody and the nuclear staining was performed with Topro-3-iodide (100 mM). Images were obtained in a confocal fluorescence microscope using appropriate wavelengths. 22 Glrx-1 antibody-stained cells were quantified using a confocal fluorescence microscope under 400 Â magnification. Random five fields were selected from each tissue section, and at least five tissue sections were examined for each group. *Po0.01 vs vector treatment.
TUNEL assay for assessment of apoptotic cell death
Immunohistochemical detection of apoptotic cells was carried out using the TUNEL method (Promega, Madison, WI, USA). The TUNEL staining was performed according to the manufacturer's instructions, as reported earlier. 25 
Western blot analysis
Western blot was performed as described earlier. 25 The following primary antibodies were obtained from Cell Signaling Technology (Boston, MA, USA): Ask1, p-Ask1 (Ser 83), FoxO-1, p-FoxO-1, caspase 3, Jnk, p-Jnk, p38MAPK, p-p38 MAPK, c-Src, and p-c-Src. The following primary antibodies: p-Akt, Akt, e-NOS, HO-1, and glyceraldehyde-6-phosphate dehydrogenase (GAPDH) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Glrx-1 antibody was obtained from Abcam (Cambridge, MA, USA).
Statistical analysis
Data are expressed as the mean ± standard error of mean (s.e.m). Analysis of variance test followed by Bonferroni's was carried out to test for any differences between mean values of all groups. If differences between groups were established, values of each treated group were compared with those of the control group by a modified t-test. Western blot data are expressed as the mean ± s.e.m. Kruskal-Wallis test was carried out to test for any differences between mean values of all groups. If differences between groups were established, values of each treated group were compared with those of the control group by a modified t-test.
